Drug ID:Drug109
Drug Name:Vidofludimus
CID:9820008
DrugBank ID:DB15446
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT03341962, , NCT05575505, , NCT05558761
Molecular Formula:C20H18FNO4
Molecular Weight:355.4 g/mol
Isomeric SMILES:COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
Synonyms:Vidofludimus; 717824-30-1; 4SC-101; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; Vidofludimus [INN]; SC12267; 2-((3-Fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)carbamoyl)cyclopent-1-enecarboxylic acid; IMU-838; SC 12267; SC-12267
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt927 9820008 Vidofludimus 27190 IL17B Homo sapiens (human) None
dt928 9820008 Vidofludimus 1723 DHODH Homo sapiens (human) None
dt929 9820008 Vidofludimus 4929 NR4A2 Homo sapiens (human) Activation
dt930 9820008 Vidofludimus 64806 IL25 Homo sapiens (human) None
dt931 9820008 Vidofludimus 1723 DHODH Homo sapiens (human) Dihydroorotate dehydrogenase inhibitor
dt932 9820008 Vidofludimus 3605 IL17A Homo sapiens (human) None
dt933 9820008 Vidofludimus 1723 DHODH Homo sapiens (human) Inhibitor
dt934 9820008 Vidofludimus 65156 Dhodh Rattus norvegicus (Norway rat) 20413687 Inhibition
dt935 9820008 Vidofludimus 1723 DHODH Homo sapiens (human) 20413687 Inhibition
dt936 9820008 Vidofludimus 56749 Dhodh Mus musculus (house mouse) 20413687 Inhibition

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT00820365 SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease PHASE2 COMPLETED 4SC AG Inflammatory Bowel Disease (IBD) DRUG: SC12267 (4SC-101) Details
EUCTR2008-005903-25-DE Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis) Not Available Not Recruiting 4SC AG inflammatory bowel disease (Crohn's disease and u… Product Name: SC12267 Product Code: SC12267 Pharm… Details
NCT03341962 Phase 2 Dose-finding IMU-838 for Ulcerative Colitis PHASE2 TERMINATED Immunic AG Ulcerative Colitis DRUG: IMU-838|DRUG: Placebo Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S09 Stem cells Transplantation mesenchymal stem cells (MSCs) MSC Crohn's disease is associated with the development of compl… Details

Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A …

PMID: 39791563
Year: 2025
Relationship Type: Treatment Score: 6.5

INTRODUCTION: Vidofludimus calcium (VidoCa) is a dihydroorotate dehydrogenase inhibitor that demonstrated efficacy in immune-related diseases. This s…

View Details